AbbVie on Twitter
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 17, 2017- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain
-
May 14, 2017- Results from data presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) further suggest that risk factors typically associated with poor clinical outcomes may be less relevant with ibrutinib treatment
-
May 09, 2017- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics
-
May 04, 2017- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics
May 03, 2017Learn about a particularly aggressive brain tumor called glioblastoma.
April 28, 2017Through our 2017 Impact by the Numbers, we’re exploring the true meaning of the phrase “remarkable impact."
Our history
 |
Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more
Societal impact
 |
Our commitment to science is a commitment to better our society. Read our 2023 ESG report
Ratings and recognition
 |
We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more
Annual report
 |
See our latest 2023 Annual Report on Form 10-K. Learn more
